Keros collaborates with Mass General on Phase 2 ALS trial of rinvatercept; presents new Phase 1 data at MDA Conf.

Keros Therapeutics, Inc.

Entered agreement with Massachusetts General Hospital for Phase 2 ALS trial within HEALEY ALS MyMatch program.
Additional Phase 1 data presented at 2026 MDA Conference: rinvatercept generally well-tolerated with no serious adverse events.
Phase 1 data showed increased muscle mass, decreased fat mass, and increased bone mineral density in healthy volunteers.
Proteomic analysis confirmed target engagement and anti-fibrotic/anti-inflammatory effects consistent with activin inhibition.
Keros plans two Phase 2 trials: one in Duchenne muscular dystrophy (DMD) and one in ALS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.